Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo

被引:17
作者
Li, Ting [1 ]
Yao, Fengjiao [1 ]
An, Yacong [1 ]
Li, Xundou [1 ]
Duan, Jinhong [1 ]
Yang, Xian-Da [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Beijing 100005, Peoples R China
关键词
aptamer; Holliday Junction; immunotherapy; CANCER-IMMUNOTHERAPY; PEMBROLIZUMAB; INHIBITORS; NIVOLUMAB; DELIVERY; CELLS;
D O I
10.3390/molecules26041067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Blocking the PD-1/PD-L1 pathway can diminish immunosuppression and enhance anticancer immunity. PD-1/PD-L1 blockade can be realized by aptamers, which have good biocompatibility and can be synthesized in quantity economically. For in vivo applications, aptamers need to evade renal clearance and nuclease digestion. Here we investigated whether DNA nanostructures could be used to enhance the function of PD-L1 aptamers. Four PD-L1 aptamers (Apt) were built into a Holliday Junction (HJ) to form a tetravalent DNA nanostructure (Apt-HJ). The average size of Apt-HJ was 13.22 nm, which was above the threshold for renal clearance. Apt-HJ also underwent partial phosphorothioate modification and had improved nuclease resistance. Compared with the monovalent PD-L1 aptamer, the tetravalent Apt-HJ had stronger affinity to CT26 colon cancer cells. Moreover, Apt-HJ markedly boosted the antitumor efficacy in vivo vs. free PD-L1 aptamers without raising systemic toxicity. The results indicate that multiple aptamers attached to a DNA nanostructure may significantly improve the function of PD-L1 aptamers in vivo.
引用
收藏
页数:12
相关论文
共 39 条
[1]   Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].
Ahmadzadeh, Mojgan ;
Johnson, Laura A. ;
Heemskerk, Bianca ;
Wunderlich, John R. ;
Dudley, Mark E. ;
White, Donald E. ;
Rosenberg, Steven A. .
BLOOD, 2009, 114 (08) :1537-1544
[2]   Immune checkpoint inhibitors of PD-L1 as cancer therapeutics [J].
Akinleye, Akintunde ;
Rasool, Zoaib .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
[3]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[4]   Aptamer Functionalized Cisplatin-Albumin Nanoparticles for Targeted Delivery to Epidermal Growth Factor Receptor Positive Cervical Cancer [J].
Chen, Yao ;
Wang, Jianjun ;
Wang, Jingshuai ;
Wang, Lei ;
Tan, Xiaohui ;
Tu, Keyao ;
Tong, Xiaowen ;
Qi, Lifeng .
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2016, 12 (04) :656-666
[5]   Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing [J].
Deleavey, Glen F. ;
Damha, Masad J. .
CHEMISTRY & BIOLOGY, 2012, 19 (08) :937-954
[6]   Tetrahedral DNA nanostructures as drug delivery and bioimaging platforms in cancer therapy [J].
Duangrat, Ratchanee ;
Udomprasert, Anuttara ;
Kangsamaksin, Thaned .
CANCER SCIENCE, 2020, 111 (09) :3164-3173
[7]   Phosphorothioates, Essential Components of Therapeutic Oligonucleotides [J].
Eckstein, Fritz .
NUCLEIC ACID THERAPEUTICS, 2014, 24 (06) :374-387
[8]   The PD-1 pathway in tolerance and autoimmunity [J].
Francisco, Loise M. ;
Sage, Peter T. ;
Sharpe, Arlene H. .
IMMUNOLOGICAL REVIEWS, 2010, 236 :219-242
[9]   Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer [J].
Ganson, Nancy J. ;
Povsic, Thomas J. ;
Sullenger, Bruce A. ;
Alexander, John H. ;
Zelenkofske, Steven L. ;
Sailstad, Jeffrey M. ;
Rusconi, Christopher P. ;
Hershfield, Michael S. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) :1610-1613
[10]   Adverse reactions after the use of sulphur hexafluoride (SonoVue) echo contrast agent [J].
Geleijnse, Marcel L. ;
Nemes, Attila ;
Vletter, Wim B. ;
Michels, Michelle ;
Soliman, Osama I. I. ;
Caliskan, Kadir ;
Galema, Tjebbe W. ;
ten Cate, Folkert J. .
JOURNAL OF CARDIOVASCULAR MEDICINE, 2009, 10 (01) :75-77